Related Experiment Video
Updated: Oct 7, 2025
The Application Of Permanent Middle Cerebral Artery Ligation in the Mouse
Published on: July 25, 2011
Mitochondrial repair as potential pharmacological target in cerebral ischemia
Ms Mandeep Kaur1, Dr Saurabh Sharma2
1Research Scholar, Department of Pharmacology, School of Pharmaceutical Sciences, CT University, Ludhiana, Punjab, India.
Insights
Mitochondrial dysfunction drives neuronal damage after cerebral ischemia. Novel therapies like mitochondria transfer and transplantation show promise for neuroprotection and neural recovery.
Area of Science:
- Neuroscience
- Cell Biology
- Pathology
Background:
- Cerebral ischemia, including stroke, is a leading cause of death and disability.
- Current treatments like rt-PA are limited, and neuroprotective agents have had limited success.
- Mitochondrial dysfunction is increasingly recognized as a key factor in ischemic neuronal damage.
Purpose of the Study:
- To review fundamental mechanisms of neuronal damage due to mitochondrial dysfunction after cerebral ischemia.
- To explore recent advances in mitochondrial interventions for treating cerebral ischemia.
- To highlight novel therapeutic strategies targeting mitochondria for neuroprotection and neural recovery.
Main Methods:
- Review of recent scientific literature on cerebral ischemia and mitochondrial dysfunction.
- Analysis of mechanisms including cell signaling, autophagy, apoptosis, ROS generation, calcium overload, mPTP opening, and mitochondrial dynamics.
- Examination of emerging therapeutic modalities such as mitochondria transfer, stem cell therapy, and transplantation.
Main Results:
- Mitochondrial dysfunction involves complex pathways leading to neuronal cell death.
- Mitochondrial biogenesis, repair, and transfer from astrocytes play crucial roles in neuroprotection.
- Mitochondria transfer and transplantation can restore cellular energy and replace damaged mitochondria.
Conclusions:
- Targeting mitochondrial dysfunction offers a promising therapeutic avenue for cerebral ischemia.
- Mitochondrial interventions, including transfer and transplantation, show potential for neural recovery.
- Novel strategies like miRNA inhibition and Sirtuin1 activation warrant further investigation for treating ischemic brain injury.
Abstract:
Cerebral ischemia and its consequences like transient ischemic attack, aneurysm and stroke are the common and devastating conditions which remain the leading cause of mortality after coronary heart disease in developed countries and are the greatest cause of disability, leaving 50% of survivors permanently disabled. Despite recognition of risk factors and mechanisms involved in the pathology of the disease, treatment of ischemic disorders is limited to thrombolytic drugs like recombinant tissue plasminogen activator (rt-PA) and clinical rendition of the neuroprotective agents have not been so successful. Recent studies evidenced the role of mitochondrial dysfunction in neuronal damage that occurred after cerebral ischemia. This review article will focus on the various fundamental mechanisms responsible for neuronal damage because of mitochondrial dysfunction including cell signaling pathways, autophagy, apoptosis/necrosis, generation of reactive oxygen species, calcium overload, the opening of membrane permeability transition pore (mPTP), mitochondrial dynamics and biogenesis. Recent studies have concerned the significant role of mitochondrial biogenesis in mitochondrial repair and transfer of healthy mitochondria from astrocytes to the damaged neurons, providing neuroprotection and neural recovery following ischemia. Novel and influential studies have evidenced the significant role of mitochondria transfer and mitochondrial transplantation in reviving cell energy and in replacement of impaired or dysfunctional mitochondria with healthy mitochondria after ischemic episode. This review article will focus on recent advances in mitochondrial interventions and exogenous therapeutic modalities like mitochondria transfer technique, employment of stem cells, mitochondrial transplantation, miRNA inhibition and mitochondrial-targeted Sirtuin1 activator for designing novel and promising treatment for cerebral ischemia induced pathological states.
